Patents by Inventor Hyun-Taek Kim

Hyun-Taek Kim has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8703732
    Abstract: The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: April 22, 2014
    Assignee: Korea Research Institute of Bioscience and Biotech
    Inventors: Nam-Soon Kim, In-Sung Song, Cheol-Hee Kim, Ga Hee Ha, Hyun-Taek Kim, So-Young Jeong, Jeong-Min Kim, Joo Heon Kim, Jin-Man Kim, Soo Young Jun
  • Publication number: 20120315284
    Abstract: The present invention relates to a pharmaceutical composition, including inhibitors for expression or activity of TIP41 protein, for prevention and treatment of cancer. When the liver cancer cell lines, showing resistance to TRAIL, are treated with TIP41 siRNA and TRAIL, apoptosis is induced in cancer cell. The same effect is found in cases of lung cancer and colon cancer with resistance against TRAIL. Moreover, this induction of apoptosis by TIP41 siRNA and TRAIL was confirmed in tumor xenograft, which was injected with Huh7 liver cancer cells and then was subjected to TIP41 siRNA transfection and TRAIL treatment. In addition, it was confirmed through animal experiments in which the tumor size has reduced and apoptosis was induced by treatment with TIP41 siRNA and TRAIL. Of note, MKK7/JNK pathway was confirmed to mediate the apoptosis induced by the application of TIP41 siRNA and TRAIL. The apoptosis were verified to be caused by the activation of MKK7/JNK signaling pathway.
    Type: Application
    Filed: April 1, 2011
    Publication date: December 13, 2012
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECH
    Inventors: Nam-Soon Kim, In-Sung Song, Cheol-Hee Kim, Ga Hee Ha, Hyun-Taek Kim, So-Young Jeong, Jeong-Min Kim, Joo Heon Kim, Jin-Man Kim, Soo Young Jun
  • Patent number: 8278285
    Abstract: The present invention relates to a diagnostic marker containing ZNF312b gene and the fragment thereof, a diagnostic method for stomach cancer and a screening method for stomach cancer inducers or inhibitors using the same. ZNF312b gene expression is specifically increased in stomach cancer. And the over-expression or the under-expression of the gene affects activation or inhibition of cell proliferation and tumor formation of a stomach cancer cell line and cell proliferation signal transduction system as well to induce stomach cancer at last. Therefore, ZNF312b marker gene can be effectively used for diagnosis of stomach cancer, construction of a stomach cancer animal model, prevention and treatment of stomach cancer and development of a stomach cancer specific anticancer agent.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 2, 2012
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Nam-Soon Kim, In-Sung Song, Nang-Su Oh, So-Young Jeong, Ga-Hee Ha, Yeo-Jin Jeon, Jeong-Min Kim, Cheol-Hee Kim, Hyun-Taek Kim
  • Publication number: 20100162420
    Abstract: The present invention relates to a diagnostic marker containing ZNF312b gene and the fragment thereof, a diagnostic method for stomach cancer and a screening method for stomach cancer inducers or inhibitors using the same. ZNF312b gene expression is specifically increased in stomach cancer. And the over-expression or the under-expression of the gene affects activation or inhibition of cell proliferation and tumor formation of a stomach cancer cell line and cell proliferation signal transduction system as well to induce stomach cancer at last. Therefore, ZNF312b marker gene can be effectively used for diagnosis of stomach cancer, construction of a stomach cancer animal model, prevention and treatment of stomach cancer and development of a stomach cancer specific anticancer agent.
    Type: Application
    Filed: August 6, 2008
    Publication date: June 24, 2010
    Inventors: Nam-Soon Kim, In-Sung Song, Nang-Su Oh, So-Young Jeong, Ga-Hee Ha, Yeo-Jin Jeon, Jeong-Min Kim, Cheol-Hee Kim, Hyun-Taek Kim
  • Publication number: 20070207230
    Abstract: Disclosed are an extract of Nelumbinis Semen (Nelumbo nucifera) having an antidepressive effect, and a pharmaceutical composition and a health food for treating depression, comprising the extract, The Nelumbinis Semen extract is prepared by extracting Nelumbinis Semen with hot water. Animal behavioral and biochemical studies revealed that the Nelumbinis Semen extract has very strong antidepressive activity and is safe to the body while reducing the side effects of conventional antidepressants. Thus, the Nelumbinis Semen extract is applicable to a composition and a health food for treating depression.
    Type: Application
    Filed: March 31, 2005
    Publication date: September 6, 2007
    Applicant: PURIMED CO., LTD.
    Inventors: Hyun-Su Bae, Moon-Kyu Kang, Jung-Wan Oh, Chong-Woon Cho, Chang-Sook Kim, Hwa-Jin Lee, In-Sop Shim, Choon-Gon Jang, Hyun Choi, Eun-Jung Ko, Chang-Jun An, Hyun-Taek Kim, Moo-Chang Hong, Min-Kyu Shin